Covid Vaccine Race

The updated vaccine efficacy and safety outcomes include 37,000-plus participants from the ongoing, multi-national trial.

The study was posted to the website clinicaltrials.gov this past Wednesday.

Authorization for a COVID-19 vaccine in the US appears imminent, bringing with it a host of concerns including the speed of development, inclusivity of clinical trials, safety of mRNA technology, and how to raise levels of trust in vulnerable populations.

Tonix Pharmaceuticals is developing a horsepox virus vector vaccine based on a historic platform which was first used for smallpox, and applying it to the world’s most recent virus.

While the antibodies declined slightly at 3 months, all participants showed elevated levels.

Initial high hopes for third vaccine available to the public, in addition to Pfizer and Moderna’s versions, are tempered as further data is sought.

The Advisory Committee on Immunization Practices (ACIP) met yesterday and decided that healthcare workers and residents in long-term care facilities will be prioritized as the first people eligible for the impending COVID-19 vaccines.

The companies are ready to ship doses immediately.

Here is everything you need to know about the second vaccine submitted for an EUA this year.

A look at the logistical questions which remain with the two leading candidates.

The former FDA commissioner weighs in on the best measures to mitigate skyrocketed new cases, and his timeline for national recovery.

OncoSec recently received an FDA IND clearance to begin a phase 1 trial.

This CDC panel discussed who should be vaccinated first and the flu-like effects from the vaccines.

Data shows their AZD1222 vaccine met its endpoint and they are preparing regulatory submission for conditional or early approval.

Here is what you need to know about BNT162b2, possibly the first vaccine regulated for COVID-19 prevention.

Phase 2 results include a large cohort of seniors in the study.

The investigational vaccine is being reported as 95% effective.

The data comes from a phase 1/2 trial with the CoronaVac vaccine.

Data show none of the treated volunteers to develop COVID-19 experienced a severe form of the disease, versus 11 given placebo.

The biotechnology has reached it COVID-19 case accrual mark, and announced plans to submit data to an independent review board.

The country halted the Sinovac investigational vaccine due to what was being reported as a serious adverse event.

The federal agency announced Novavax’s, NVX-CoV2373, was granted this designation.

The company is still awaiting its threshold for total COVID-19 infections in its 44,000-patient assessment. Nonetheless, they believe they have made history.

The company recently announced it was in a phase 1 trial.

The company is planning to move forward after receiving a recommendation from the DSMB to start up the trial again.

The conclusion to the independent safety review punctuates a 50-day period of scrutiny and discussion around 2 non-fatal adverse events reported in patients.

Its phase 3 COVE trial enrollment is complete and the company is working towards its goal of FDA approval.

The participant was taking a placebo and the trial will continue according to initial reports.

Many unknowns remain as the scientific community focuses on its goal of issuing a vaccine for COVID-19.